Dew, what do you make of Merck's tortoise-like development program with Ridaforolimus? Have they just 'given in' to Afinitor, or are they just a bunch of bumbling fools wondering which direction to take the drug? So much for "best in class" for Ridaforolimus. Don't hear that from Berger anymore, huh?